erlotinib (Tarceva®)

Status: Excluded due to NICE appraisal
Product meets AWMSG exclusion due to NICE appraisal TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (replaced TA175, terminated appraisal)
Medicine details
Medicine name	erlotinib (Tarceva®)
Formulation	film-coated tablet
Reference number	133
Indication	TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (replaced TA175, terminated appraisal)
Company	Roche Products Ltd
BNF chapter	Malignant disease & immunosuppression
Assessment type	N/A
Status	Excluded due to NICE appraisal
Date of issue	09/03/2006
NICE guidance	TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (replaced TA175, terminated appraisal)